RÉSUMÉ
Solid organ transplant recipients have an elevated incidence of thyroid cancer. We evaluated a wide range of potential risk factors in a cohort of 229 300 U.S. solid organ transplant recipients linked with 15 stage/regional cancer registries (1987-2012). Incidence rate ratios (IRRs) were adjusted for age, sex, race/ethnicity, transplanted organ, year of transplantation, and time since transplantation. Hazard ratios (HRs) for death and/or graft failure were adjusted for age, sex, race/ethnicity, transplanted organ, and year of transplantation. After transplantation, 356 thyroid cancers were diagnosed. Thyroid cancer incidence was 2.50-fold higher in transplant recipients than the general population (95% confidence interval [CI] 2.25-2.77). Among recipients of different organs, kidney recipients had the highest incidence of thyroid cancer (IRR = 1.26, 95% CI 1.03-1.53). Elevated thyroid cancer incidence was associated with cholestatic liver disease/cirrhosis as an indication for liver transplantation (IRR = 1.69, 95% CI 1.09-2.63), hypertensive nephrosclerosis as an indication for kidney transplantation (IRR = 1.41, 95% CI 1.03-1.94), and longer prior dialysis among kidney recipients (5+ vs. <1 year, IRR = 1.92, 95% CI 1.32-2.80; p-trend <0.01). Posttransplantation diagnosis of thyroid cancer was associated with modestly increased risk of death (HR = 1.33, 95% CI 1.02-1.73). Overall, our results suggest that end-stage organ disease and longer duration of dialysis may contribute to higher thyroid cancer incidence in transplant recipients.
Sujet(s)
Transplantation d'organe/effets indésirables , Dialyse rénale/statistiques et données numériques , Tumeurs de la thyroïde/épidémiologie , Tumeurs de la thyroïde/étiologie , Adulte , Facteurs âges , Sujet âgé , Femelle , Études de suivi , Humains , Incidence , Mâle , Adulte d'âge moyen , Pronostic , Enregistrements , Facteurs de risque , Receveurs de transplantation , États-Unis/épidémiologieRÉSUMÉ
Renal cell carcinoma (RCC) is a common malignancy following kidney transplantation. We describe RCC risk and examine RCC risk factors among US kidney recipients (1987-2010). The Transplant Cancer Match Study links the US transplant registry with 15 cancer registries. Standardized incidence ratios (SIRs) were used to compare RCC risk (overall and for clear cell [ccRCC] and papillary subtypes) to the general population. Associations with risk factors were assessed using Cox models. We identified 683 RCCs among 116 208 kidney recipients. RCC risk was substantially elevated compared with the general population (SIR 5.68, 95% confidence interval 5.27-6.13), especially for papillary RCC (SIR 13.3 versus 3.98 for ccRCC). Among kidney recipients, RCC risk was significantly elevated for blacks compared to whites (hazard ratio [HR] 1.50) and lower in females than males (HR 0.56). RCC risk increased with prolonged dialysis preceding transplantation (p-trend < 0.0001). Risk was variably associated for RCC subtypes with some medical conditions that were indications for transplantation: ccRCC risk was reduced with polycystic kidney disease (HR 0.54), and papillary RCC was increased with hypertensive nephrosclerosis (HR 2.02) and vascular diseases (HR 1.86). In conclusion, kidney recipients experience substantially elevated risk of RCC, especially for papillary RCC, and multiple factors contribute to these cancers.
Sujet(s)
Néphrocarcinome/étiologie , Rejet du greffon/étiologie , Tumeurs du rein/étiologie , Transplantation rénale/effets indésirables , Complications postopératoires , Adulte , Néphrocarcinome/épidémiologie , Femelle , Études de suivi , Débit de filtration glomérulaire , Rejet du greffon/épidémiologie , Humains , Incidence , Défaillance rénale chronique/chirurgie , Tests de la fonction rénale , Tumeurs du rein/épidémiologie , Mâle , Adulte d'âge moyen , Pronostic , Facteurs de risque , États-Unis/épidémiologieRÉSUMÉ
US transplant centers are required to report cancers in transplant recipients to the transplant network. The accuracy and completeness of these data, collected in the Scientific Registry of Transplant Recipients (SRTR), are unknown. We compared diagnoses in the SRTR and 15 linked cancer registries for colorectal, liver, lung, breast, prostate and kidney cancers; melanoma; and non-Hodgkin lymphoma (NHL). Among 187 384 transplants, 9323 cancers were documented in the SRTR or cancer registries. Only 36.8% of cancers were in both, with 47.5% and 15.7% of cases additionally documented solely in cancer registries or the SRTR, respectively. Agreement between the SRTR and cancer registries varied (kappa = 0.28 for liver cancer and kappa = 0.52-0.66 for lung, prostate, kidney, colorectum, and breast cancers). Upon evaluation, some NHLs documented only in cancer registries were identified in the SRTR as another type of posttransplant lymphoproliferative disorder. Some SRTR-only cases were explained by miscoding (colorectal cancer instead of anal cancer, metastases as lung or liver cancers) or missed matches with cancer registries, partly due to recipients' outmigration from catchment areas. Estimated sensitivity for identifying cancer was 52.5% for the SRTR and 84.3% for cancer registries. In conclusion, SRTR cancer data are substantially incomplete, limiting their usefulness for surveillance and research.
Sujet(s)
Collecte de données/normes , Tumeurs/diagnostic , Transplantation d'organe , Enregistrements/normes , Adulte , Femelle , Humains , Incidence , Mâle , Tumeurs/épidémiologie , Pronostic , États-Unis/épidémiologieRÉSUMÉ
Solid organ transplant recipients have increased colorectal cancer (CRC) risk. We assessed CRC risk among transplant recipients and identified factors contributing to this association. The US transplant registry was linked to 15 population-based cancer registries (1987-2010). We compared CRC risk in recipients to the general population by using standardized incidence ratios (SIRs) and identified CRC risk factors by using Poisson regression. Based on 790 cases of CRC among 224 098 transplant recipients, the recipients had elevated CRC risk (SIR 1.12, 95% confidence interval [CI] 1.04 to 1.20). The increase was driven by an excess of proximal colon cancer (SIR 1.69, 95% CI 1.53 to 1.87), while distal colon cancer was not increased (SIR 0.93, 95% CI 0.80 to 1.07), and rectal cancer was reduced (SIR 0.64, 95% CI 0.54 to 0.76). In multivariate analyses, CRC was increased markedly in lung recipients with cystic fibrosis (incidence rate ratio [IRR] 12.3, 95% CI 6.94 to 21.9, vs. kidney recipients). Liver recipients with primary sclerosing cholangitis and inflammatory bowel disease also had elevated CRC risk (IRR 5.32, 95% CI 3.73 to 7.58). Maintenance therapy with cyclosporine and azathioprine was associated with proximal colon cancer (IRR 1.53, 95% CI 1.05 to 2.23). Incidence was not elevated in a subgroup of kidney recipients treated with tacrolimus and mycophenolate mofetil, pointing to the relevance of the identified risk factors. Transplant recipients have increased proximal colon cancer risk, likely related to underlying medical conditions (cystic fibrosis and primary sclerosing cholangitis) and specific immunosuppressive regimens.
Sujet(s)
Tumeurs colorectales/étiologie , Rejet du greffon/étiologie , Transplantation d'organe/effets indésirables , Complications postopératoires , Enregistrements , Adulte , Sujet âgé , Tumeurs colorectales/épidémiologie , Femelle , Études de suivi , Survie du greffon , Humains , Incidence , Mâle , Adulte d'âge moyen , Pronostic , Appréciation des risques , Facteurs de risque , Receveurs de transplantation , États-Unis/épidémiologieRÉSUMÉ
Prospective cohorts have played a major role in understanding the contribution of diet, physical activity, medical conditions, and genes to the development of many diseases, but have not been widely used for occupational exposures. Studies in agriculture are an exception. We draw upon our experience using this design to study agricultural workers to identify conditions that might foster use of prospective cohorts to study other occupational settings. Prospective cohort studies are perceived by many as the strongest epidemiologic design. It allows updating of information on exposure and other factors, collection of biologic samples before disease diagnosis for biomarker studies, assessment of effect modification by genes, lifestyle, and other occupational exposures, and evaluation of a wide range of health outcomes. Increased use of prospective cohorts would be beneficial in identifying hazardous exposures in the workplace. Occupational epidemiologists should seek opportunities to initiate prospective cohorts to investigate high priority, occupational exposures.
Sujet(s)
Exposition professionnelle/analyse , Médecine du travail , Études prospectives , Maladies des agriculteurs/étiologie , Méthodologie en recherche épidémiologique , HumainsRÉSUMÉ
BACKGROUND: Abdominal radiotherapy for testicular cancer (TC) increases risk for second stomach cancer, although data on the radiation dose-response relationship are sparse. METHODS: In a cohort of 22,269 5-year TC survivors diagnosed during 1959-1987, doses to stomach subsites were estimated for 92 patients who developed stomach cancer and 180 matched controls. Chemotherapy details were recorded. Odds ratios (ORs) were estimated using logistic regression. RESULTS: Cumulative incidence of second primary stomach cancer was 1.45% at 30 years after TC diagnosis. The TC survivors who received radiotherapy (87 (95%) cases, 151 (84%) controls) had a 5.9-fold (95% confidence interval (CI) 1.7-20.7) increased risk of stomach cancer. Risk increased with increasing stomach dose (P-trend<0.001), with an OR of 20.5 (3.7-114.3) for ⩾50.0 Gy compared with <10 Gy. Radiation-related risks remained elevated ⩾20 years after exposure (P<0.001). Risk after any chemotherapy was not elevated (OR=1.1; 95% CI 0.5-2.5; 14 cases and 23 controls). CONCLUSIONS: Radiotherapy for TC involving parts of the stomach increased gastric cancer risk for several decades, with the highest risks after stomach doses of ⩾30 Gy. Clinicians should be aware of these excesses when previously irradiated TC survivors present with gastrointestinal symptoms and when any radiotherapy is considered in newly diagnosed TC patients.
Sujet(s)
Tumeurs radio-induites/étiologie , Tumeurs de l'estomac/étiologie , Tumeurs du testicule/radiothérapie , Adolescent , Adulte , Sujet âgé , Études cas-témoins , Études de cohortes , Relation dose-effet des rayonnements , Femelle , Humains , Incidence , Mâle , Adulte d'âge moyen , Dosimétrie en radiothérapie , Survivants , Jeune adulteRÉSUMÉ
BACKGROUND: Although elevated risks of pancreatic cancer have been observed in long-term survivors of Hodgkin lymphoma (HL), no prior study has assessed the risk of second pancreatic cancer in relation to radiation dose and specific chemotherapeutic agents. PATIENTS AND METHODS: We conducted an international case-control study within a cohort of 19 882 HL survivors diagnosed from 1953 to 2003 including 36 cases and 70 matched controls. RESULTS: Median ages at HL and pancreatic cancer diagnoses were 47 and 60.5 years, respectively; median time to pancreatic cancer was 19 years. Pancreatic cancer risk increased with increasing radiation dose to the pancreatic tumor location (Ptrend = 0.005) and increasing number of alkylating agent (AA)-containing cycles of chemotherapy (Ptrend = 0.008). The odds ratio (OR) for patients treated with both subdiaphragmatic radiation (≥10 Gy) and ≥6 AA-containing chemotherapy cycles (13 cases, 6 controls) compared with patients with neither treatment was 17.9 (95% confidence interval 3.5-158). The joint effect of these two treatments was significantly greater than additive (P = 0.041) and nonsignificantly greater than multiplicative (P = 0.29). Especially high risks were observed among patients receiving ≥8400 mg/m(2) of procarbazine with nitrogen mustard or ≥3900 mg/m(2) of cyclophosphamide. CONCLUSION: Our study demonstrates for the first time that both radiotherapy and chemotherapy substantially increase pancreatic cancer risks among HL survivors treated in the past. These findings extend the range of nonhematologic cancers associated with chemotherapy and add to the evidence that the combination of radiotherapy and chemotherapy can lead to especially large risks.
Sujet(s)
Maladie de Hodgkin/complications , Tumeurs radio-induites/épidémiologie , Tumeurs du pancréas/épidémiologie , Tumeurs du pancréas/étiologie , Adulte , Sujet âgé , Études cas-témoins , Relation dose-effet des rayonnements , Femelle , Maladie de Hodgkin/traitement médicamenteux , Maladie de Hodgkin/anatomopathologie , Maladie de Hodgkin/radiothérapie , Humains , Mâle , Adulte d'âge moyen , Tumeurs radio-induites/anatomopathologie , Tumeurs du pancréas/induit chimiquement , Radiothérapie/effets indésirables , Facteurs de risqueRÉSUMÉ
Solid organ transplant recipients have elevated cancer risks, owing in part to pharmacologic immunosuppression. However, little is known about risks for hematologic malignancies of myeloid origin. We linked the US Scientific Registry of Transplant Recipients with 15 population-based cancer registries to ascertain cancer occurrence among 207 859 solid organ transplants (1987-2009). Solid organ transplant recipients had a significantly elevated risk for myeloid neoplasms, with standardized incidence ratios (SIRs) of 4.6 (95% confidence interval 3.8-5.6; N=101) for myelodysplastic syndromes (MDS), 2.7 (2.2-3.2; N=125) for acute myeloid leukemia (AML), 2.3 (1.6-3.2; N=36) for chronic myeloid leukemia and 7.2 (5.4-9.3; N=57) for polycythemia vera. SIRs were highest among younger individuals and varied by time since transplantation and organ type (Poisson regression P<0.05 for all comparisons). Azathioprine for initial maintenance immunosuppression increased risk for MDS (P=0.0002) and AML (2-5 years after transplantation, P=0.0163). Overall survival following AML/MDS among transplant recipients was inferior to that of similar patients reported to US cancer registries (log-rank P<0.0001). Our novel finding of increased risks for specific myeloid neoplasms after solid organ transplantation supports a role for immune dysfunction in myeloid neoplasm etiology. The increased risks and inferior survival should heighten clinician awareness of myeloid neoplasms during follow-up of transplant recipients.
Sujet(s)
Leucémie myéloïde/épidémiologie , Leucémie myéloïde/étiologie , Transplantation d'organe/effets indésirables , Adolescent , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Enfant , Enfant d'âge préscolaire , Femelle , Humains , Incidence , Nourrisson , Nouveau-né , Leucémie myéloïde/diagnostic , Mâle , Adulte d'âge moyen , Mortalité , Enregistrements , Risque , États-Unis/épidémiologie , Jeune adulteRÉSUMÉ
Transplant recipients have elevated cancer risk including risk of human papillomavirus (HPV)-associated cancers of the cervix, anus, penis, vagina, vulva and oropharynx. We examined the incidence of HPV-related cancers in 187 649 US recipients in the Transplant Cancer Match Study. Standardized incidence ratios (SIRs) compared incidence rates to the general population, and incidence rate ratios (IRRs) compared rates across transplant subgroups. We observed elevated incidence of HPV-related cancers (SIRs: in situ 3.3-20.3, invasive 2.2-7.3), except for invasive cervical cancer (SIR 1.0). Incidence increased with time since transplant for vulvar, anal and penile cancers (IRRs 2.1-4.6 for 5+ vs. <2 years). Immunophenotype, characterized by decreased incidence with HLA DRB1:13 and increased incidence with B:44, contributed to susceptibility at several sites. Use of specific immunosuppressive medications was variably associated with incidence; for example, tacrolimus, was associated with reduced incidence for some anogenital cancers (IRRs 0.4-0.7) but increased incidence of oropharyngeal cancer (IRR 2.1). Thus, specific features associated with recipient characteristics, transplanted organs and medications are associated with incidence of HPV-related cancers after transplant. The absence of increased incidence of invasive cervical cancer highlights the success of cervical screening in this population and suggests a need for screening for other HPV-related cancers.
Sujet(s)
Tumeurs de l'anus/complications , Immunosuppression thérapeutique/effets indésirables , Transplantation d'organe/effets indésirables , Tumeurs de l'oropharynx/complications , Infections à papillomavirus/complications , Tumeurs du pénis/complications , Tumeurs du col de l'utérus/complications , Tumeurs de la vulve/complications , Adolescent , Adulte , Tumeurs de l'anus/épidémiologie , Tumeurs de l'anus/virologie , Études de cohortes , Femelle , Humains , Incidence , Mâle , Adulte d'âge moyen , Tumeurs de l'oropharynx/épidémiologie , Tumeurs de l'oropharynx/virologie , Infections à papillomavirus/épidémiologie , Infections à papillomavirus/virologie , Tumeurs du pénis/épidémiologie , Tumeurs du pénis/virologie , Enregistrements , Tacrolimus/effets indésirables , États-Unis/épidémiologie , Tumeurs du col de l'utérus/épidémiologie , Tumeurs du col de l'utérus/virologie , Tumeurs de la vulve/épidémiologie , Tumeurs de la vulve/virologie , Jeune adulteRÉSUMÉ
BACKGROUND: Radiotherapy for breast cancer may expose the esophagus to ionizing radiation, but no study has evaluated esophageal cancer risk after breast cancer associated with radiation dose or systemic therapy use. DESIGN: Nested case-control study of esophageal cancer among 289 748 ≥5-year survivors of female breast cancer from five population-based cancer registries (252 cases, 488 individually matched controls), with individualized radiation dosimetry and information abstracted from medical records. RESULTS: The largest contributors to esophageal radiation exposure were supraclavicular and internal mammary chain treatments. Esophageal cancer risk increased with increasing radiation dose to the esophageal tumor location (P(trend )< 0.001), with doses of ≥35 Gy associated with an odds ratio (OR) of 8.3 [95% confidence interval (CI) 2.7-28]. Patients with hormonal therapy ≤5 years preceding esophageal cancer diagnosis had lower risk (OR = 0.4, 95% CI 0.2-0.8). Based on few cases, alkylating agent chemotherapy did not appear to affect risk. Our data were consistent with a multiplicative effect of radiation and other esophageal cancer risk factors (e.g. smoking). CONCLUSIONS: Esophageal cancer is a radiation dose-related complication of radiotherapy for breast cancer, but absolute risk is low. At higher esophageal doses, the risk warrants consideration in radiotherapy risk assessment and long-term follow-up.
Sujet(s)
Survie sans rechute , Tumeurs de l'oesophage/mortalité , Tumeurs radio-induites/étiologie , Seconde tumeur primitive/étiologie , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Consommation d'alcool , Indice de masse corporelle , Tumeurs du sein/radiothérapie , Études cas-témoins , Relation dose-effet des rayonnements , Tumeurs de l'oesophage/épidémiologie , Femelle , Humains , Adulte d'âge moyen , Tumeurs radio-induites/traitement médicamenteux , Tumeurs radio-induites/radiothérapie , Seconde tumeur primitive/traitement médicamenteux , Seconde tumeur primitive/radiothérapie , Dosimétrie en radiothérapie , Risque , Facteurs de risque , Fumer , SurvivantsRÉSUMÉ
Several epidemiological studies suggested an association between the risk of bladder cancer and the exposure to trihalomethanes (THMs), the main disinfection by-products (DBPs) of chlorinated water. A previous pooled analysis of case-control studies from North America and Europe estimated a summarized dose-response relation. For policy guidance of drinking water disinfection in Europe and because major differences exist in water disinfection practices and DBPs occurrence between both continents, specific risk estimates for bladder cancer in relation to DBPs exposure for European populations were needed. We conducted a pooled and a two-stage random-effect meta-analyses of three European case-control studies from France, Finland, and Spain (5467 individuals: 2381 cases and 3086 controls). Individual exposure to THMs was calculated combining information on residential history, estimates of the average total THMs (TTHM) level in tap water at the successive residences and personal water consumption. A significant odds-ratio was observed for men exposed to an average residential TTHM level > 50 µg/l (OR = 1.47 (1.05; 2.05)) when compared to men exposed to levels ≤ 5 µg/l. The linear trend of the exposure-risk association was significant (p = 0.01). Risks increased significantly for exposure levels above 25 µg/l and with more than 30 years of exposure to chlorinated water, but were mainly driven by the level rather than the duration of exposure. No significant association was found among women or with cumulative exposure through ingestion. There was no evidence of a differential exposure-response relation for TTHM and bladder cancer in Europe and North America. Consequently, a global exposure-risk relation based on 4351 cases and 7055 controls is now available.
Sujet(s)
Trihalogénométhanes/toxicité , Tumeurs de la vessie urinaire/induit chimiquement , Polluants chimiques de l'eau/toxicité , Purification de l'eau/méthodes , Alimentation en eau/analyse , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Études cas-témoins , Désinfection , Relation dose-effet des médicaments , Consommation de boisson , Exposition environnementale/effets indésirables , Exposition environnementale/analyse , Femelle , Humains , Mâle , Adulte d'âge moyen , Trihalogénométhanes/analyse , Tumeurs de la vessie urinaire/épidémiologie , Polluants chimiques de l'eau/analyseSujet(s)
Carbone/métabolisme , Réparation de l'ADN/génétique , Lymphome folliculaire/génétique , Lymphome B diffus à grandes cellules/génétique , Modèles génétiques , Protéines tumorales/génétique , Polymorphisme de nucléotide simple , Adulte , Sujet âgé , Femelle , Analyse de profil d'expression de gènes , Variation génétique , Humains , Estimation de Kaplan-Meier , Lymphome folliculaire/métabolisme , Lymphome folliculaire/mortalité , Lymphome B diffus à grandes cellules/métabolisme , Lymphome B diffus à grandes cellules/mortalité , Mâle , Adulte d'âge moyen , Pronostic , Modèles des risques proportionnels , Courbe ROC , Risque , Jeune adulteRÉSUMÉ
The protein encoded by the CHEK2 gene is involved in cellular repair of DNA damage. The truncating mutation, CHEK2*1100delC, seems to increase the risk for breast cancer. We investigated whether the CHEK2*1100delC mutation carrier status increases the risk for asynchronous contralateral breast cancer (CBC) and whether it interacts with radiation therapy (RT) or chemotherapy in regard to CBC risk. The germline mutation frequency was assessed in 708 women with CBC and 1395 women with unilateral breast cancer (UBC) in the Women's Environment, Cancer and Radiation Epidemiology (WECARE) Study whose first primary breast cancer was diagnosed before age 55 years and during 1985--1999. Seven women with CBC (1.0%) and 10 women with UBC (0.7%) were CHEK2*1100delC variant carriers (rate ratio (RR)=1.8, 95% confidence interval (CI)=0.6-5.4 for CBC vs UBC). Carriers who received RT for their first breast cancer, compared with non-carriers not treated with RT, had an RR of developing CBC of 2.6 (95% CI=0.8-8.7). We found no significant associations between the CHEK2*1100delC mutation and CBC overall or among those treated with RT. However, the sampling variability was such that modest increases in risk could not be excluded. Nonetheless, because this is a rare mutation, it is unlikely to explain a major fraction of CBC in the population.
Sujet(s)
Tumeurs du sein/génétique , Mutation germinale/génétique , Protein-Serine-Threonine Kinases/génétique , Tumeurs du sein/épidémiologie , Tumeurs du sein/radiothérapie , Études cas-témoins , Checkpoint kinase 2 , Femelle , Génotype , Humains , Adulte d'âge moyen , Protein-Serine-Threonine Kinases/métabolisme , Facteurs de risque , Programme SEERRÉSUMÉ
BACKGROUND AND OBJECTIVE: Methylating agents are effective chemotherapy agents for Hodgkin lymphoma, but are associated with the development of second primary cancers. Cytotoxicity of methylating agents is mediated primarily by the DNA mismatch repair (MMR) system. Loss of MLH1, a major component of DNA MMR, results in tolerance to the cytotoxic effects of methylating agents and persistence of mutagenised cells at high risk of malignant transformation. We hypothesised that a common substitution in the basal promoter of MLH1 (position -93, rs1800734) modifies the risk of cancer after methylating chemotherapy. METHODS: 133 patients who developed cancer following chemotherapy and/or radiotherapy (n = 133), 420 patients diagnosed with de novo myeloid leukaemia, 242 patients diagnosed with primary Hodgkin lymphoma, and 1177 healthy controls were genotyped for the MLH1 -93 polymorphism by allelic discrimination polymerase chain reaction (PCR) and restriction fragment length polymorphism assay. Odds ratios and 95% confidence intervals for cancer risk by MLH1 -93 polymorphism status, and stratified by previous exposure to methylating chemotherapy, were calculated using unconditional logistic regression. RESULTS: Carrier frequency of the MLH1 -93 variant was higher in patients who developed therapy related acute myeloid leukaemia (t-AML) (75.0%, n = 12) or breast cancer (53.3%. n = 15) after methylating chemotherapy for Hodgkin lymphoma compared to patients without previous methylating exposure (t-AML, 30.4%, n = 69; breast cancer patients, 27.2%, n = 22). The MLH1 -93 variant allele was also over-represented in t-AML cases when compared to de novo AML cases (36.9%, n = 420) and healthy controls (36.3%, n = 952), and was associated with a significantly increased risk of developing t-AML (odds ratio 5.31, 95% confidence interval 1.40 to 20.15), but only in patients previously treated with a methylating agent. CONCLUSIONS: These data support the hypothesis that the common polymorphism at position -93 in the core promoter of MLH1 defines a risk allele for the development of cancer after methylating chemotherapy for Hodgkin lymphoma. However, replication of this finding in larger studies is suggested.
Sujet(s)
Protéines adaptatrices de la transduction du signal/génétique , Antinéoplasiques alcoylants/effets indésirables , Maladie de Hodgkin/traitement médicamenteux , Maladie de Hodgkin/génétique , Seconde tumeur primitive/étiologie , Protéines nucléaires/génétique , Polymorphisme génétique , Adolescent , Adulte , Sujet âgé , Allèles , Séquence nucléotidique , Études cas-témoins , Méthylation de l'ADN , Amorces ADN/génétique , Réparation de l'ADN/génétique , Femelle , Humains , Leucémie aigüe myéloïde/induit chimiquement , Leucémie aigüe myéloïde/étiologie , Leucémie aigüe myéloïde/génétique , Mâle , Adulte d'âge moyen , Protéine-1 homologue de MutL , Seconde tumeur primitive/induit chimiquement , Seconde tumeur primitive/génétique , Régions promotrices (génétique) , Facteurs de risqueRÉSUMÉ
OBJECTIVE: To investigate the association between obesity and risk of renal cell carcinoma and to examine whether the association is modified by physical activity. SUBJECTS: A population-based case-control study of 406 patients with renal cell carcinoma and 2434 controls conducted in Iowa. METHODS: Information was collected on weight at the ages 20-29, 40-49, and 60-69 years, height, nonoccupational physical activity, diet, and other lifestyle factors. Renal cell carcinoma risk was estimated by odds ratios (ORs) and 95% confidence intervals (CIs), adjusting for age, total energy intake, and other confounding factors. RESULTS: Height and total energy intake were not associated with risk in either sex. In men, neither physical activity nor level of obesity in any period of life was significantly associated with risk. In women, lower physical activity was associated with higher risk (OR=2.5; 95% CI=1.2-5.2 comparing exercise <1 time/month to >1 time/day). Compared with women in the lowest quartile for BMI, the risks of renal cell carcinoma for women in the highest 10% of BMI in their 20s, 40s, and 60s were 1.4 (CI=0.6-3.1), 1.9 (CI=0.9-4.2), and 2.3 (CI=0.9-6.0), respectively. When analyses were limited to self-respondent data, the corresponding ORs were 2.9 (CI=1.2-7.4), 3.2 (CI=1.3-7.5), and 2.1 (CI=0.7-6.4), respectively. There was little evidence that physical activity modifies the association of BMI with renal cell carcinoma. CONCLUSION: Nonoccupational physical activity was inversely associated and obesity was positively associated with risk of renal cell carcinoma among women. The risk appeared to be greater for women in the highest 10% of BMI in their 40s. Our finding of little evidence of an interaction between physical activity and BMI requires confirmation.
Sujet(s)
Indice de masse corporelle , Néphrocarcinome/étiologie , Tumeurs du rein/étiologie , Activité motrice , Obésité/complications , Adulte , Sujet âgé , Anthropométrie , Études cas-témoins , , Régime alimentaire , Ration calorique , Exercice physique , Femelle , Humains , Mode de vie , Mâle , Adulte d'âge moyen , Facteurs de risque , Facteurs sexuelsRÉSUMÉ
BACKGROUND: The use of paraffin wax embedded tissue samples as a source of DNA for genotype analysis has been limited because of difficulties in DNA extraction and single nucleotide polymorphism (SNP) analysis. AIMS: To test the feasibility of applying the combination of a commonly used DNA isolation procedure, PureGene, and a high throughput SNP analysis method, the polymerase chain reaction (PCR)-INVADER assay, to genotype several types of paraffin wax embedded breast tissues. METHODS: Twenty formalin fixed, paraffin wax blocks were obtained from five participants in the Iowa women's health study. Each participant provided several types of tissue including normal lymph node, normal nipple/areola tissue, inflammatory/fibrotic breast tissue, or normal breast tissue, and tumour tissue. RESULTS: Good quality DNA (260/280 ratio >1.6) was obtained from all tissues. Normal lymph nodes yielded the largest amount of DNA (97.1 mug). DNA obtained from the samples was tested for a germline C1183T polymorphism in the MnSOD gene by three methods-PCR-RFLP (restriction fragment length polymorphism), INVADER assay, and PCR-INVADER assay. Of the 20 samples, PCR-RFLP genotyped 16, the PCR-INVADER assay 18, and the INVADER assay two. This methodology was then used to analyse five additional genotypes and confirmed the general applicability of the method. CONCLUSIONS: This study demonstrated the feasibility of (1) using several paraffin wax embedded breast tissues as a source of DNA for germline genetic analysis, with lymph nodes providing the highest yield, and (2) using the combination of a common extraction method with a high throughput SNP analysis method, the PCR-INVADER assay.
Sujet(s)
Tumeurs du sein/génétique , ADN tumoral/isolement et purification , Réparation de l'ADN/génétique , ADN tumoral/génétique , Études de faisabilité , Femelle , Génotype , Humains , Inclusion en paraffine , Réaction de polymérisation en chaîne/méthodes , Polymorphisme de restriction , Polymorphisme de nucléotide simple , Superoxide dismutase/génétiqueSujet(s)
Agriculture , Immunité/effets des médicaments et des substances chimiques , Pesticides/pharmacologie , Zea mays , Adulte , Marqueurs biologiques/analyse , Humains , Immunité/immunologie , Mâle , Adulte d'âge moyen , Pesticides/toxicité , Enquêtes et questionnaires , Lymphocytes T/effets des médicaments et des substances chimiques , Lymphocytes T/immunologie , Lymphocytes T/métabolismeRÉSUMÉ
The Agricultural Health Study (www.aghealth.org) is a cohort of 89,658 pesticide applicators and their spouses from Iowa and North Carolina assembled between 1993 and 1997 to evaluate riskfactorsfor disease in ruralfarm populations. This prospective study is just now reaching sufficient maturity for analysis of many disease endpoints. Nonetheless, several analyses have already provided interesting and important leads regarding disease patterns in agricultural populations and etiologic clues for the general population. Compared to the mortality experience of the general population in the two states (adjusted for race, gender, age and calendar time), the cohort experienced a very low mortality rate overall and for many specific causes and a low rate of overall cancer incidence. A few cancers, however, appear elevated, including multiple myeloma and cancers of the lip, gallbladder, ovary, prostate, and thyroid, but numbers are small for many cancers. A study of prostate cancer found associations with exposure to several pesticides, particularly among individuals with a family history of prostate cancer. Links to pesticides and other agricultural factors have been found for injuries, retinal degeneration, and respiratory wheeze. Methodological studies have determined that information collected by interview is unbiased and reliable. A third round of interviews scheduled to begin in 2005 will collect additional information on agricultural exposures and health outcomes. The study can provide data to address many health issues in the agricultural community. The study investigators welcome collaboration with interested scientists.
Sujet(s)
Maladies des agriculteurs/épidémiologie , Pesticides , Accidents du travail/statistiques et données numériques , Maladies des agriculteurs/étiologie , Maladies des agriculteurs/mortalité , Femelle , Humains , Entretiens comme sujet , Iowa/épidémiologie , Mâle , Adulte d'âge moyen , Caroline du Nord/épidémiologie , Études prospectives , Facteurs de risque , Conjoints , Plaies et blessuresRÉSUMÉ
BACKGROUND: Alachlor is the active ingredient in pre-emergent herbicide formulations that have been used widely on corn, soybeans, and other crops. It has been found to cause nasal, stomach, and thyroid tumours in rodent feeding studies at levels that are much higher than likely human exposures. AIMS: To evaluate mortality rates from 1968 to 1999 and cancer incidence rates from 1969 to 1999 for alachlor manufacturing workers at a plant in Muscatine, Iowa. METHODS: Worker mortality and cancer incidence rates were compared to corresponding rates for the Iowa state general population. Analyses addressed potential intensity and duration of exposure. RESULTS: For workers with any period of high alachlor exposure, mortality from all causes combined was lower than expected (42 observed deaths, SMR 64, 95% CI 46 to 86) and cancer mortality was slightly lower than expected (13 observed deaths, SMR 79, 95% CI 42 to 136). Cancer incidence for workers with potential high exposure was similar to that for Iowa residents, both overall (29 observed cases, SIR 123, 95% CI 82 to 177) and for workers exposed for five or more years and with at least 15 years since first exposure (eight observed cases, SIR 113, 95% CI 49 to 224). There were no cases of nasal, stomach, or thyroid cancer. CONCLUSIONS: There were no cancers of the types found in toxicology studies and no discernible relation between cancer incidence for any site and years of alachlor exposure or time since first exposure. Despite the small size of this population, the findings are important because these workers had chronic exposure potential during extended manufacturing campaigns, while use in agriculture is typically limited to a few days or weeks each year.
Sujet(s)
Acétamides/intoxication , Industrie chimique , Herbicides/intoxication , Tumeurs/induit chimiquement , Maladies professionnelles/induit chimiquement , Adulte , Études de cohortes , Surveillance de l'environnement/méthodes , Surveillance épidémiologique , Femelle , Humains , Incidence , Iowa/épidémiologie , Leucémie myéloïde chronique BCR-ABL positive/induit chimiquement , Leucémie myéloïde chronique BCR-ABL positive/épidémiologie , Leucémie myéloïde chronique BCR-ABL positive/mortalité , Mâle , Adulte d'âge moyen , Tumeurs/épidémiologie , Tumeurs/mortalité , Maladies professionnelles/épidémiologie , Maladies professionnelles/mortalité , Exposition professionnelle/effets indésirables , Répartition par sexeRÉSUMÉ
Because few studies have assessed the accuracy of lung cancer histologic diagnoses reported by state cancer registries, we examined whether the Iowa Surveillance, Epidemiology, and End Results Cancer Registry (i.e., the Iowa Cancer Registry)-reported lung cancer histologic diagnoses were reliable. We investigated agreement between lung cancer histologic types reported for 413 patients with lung cancer by the Iowa Cancer Registry and those obtained through an independent review of diagnostic slides. Among lung cancer histologic types, small-cell carcinoma had the highest sensitivity (94.1%, 95% confidence interval [CI] = 85.6% to 98.4%), positive predictive value (94.1%, 95% CI = 85.6% to 98.4%), negative predictive value (98.8%, 95% CI = 96.9% to 99.7%), and highest percent exact agreement (98.0%, 95% CI = 96.6% to 99.4%). The lowest sensitivity (21.9%, 95% CI = 9.3% to 40.0%) and positive predictive value (23.3%, 95% CI = 9.9% to 42.3%) were noted for large-cell carcinoma, probably because other more specific features of adenocarcinoma or squamous carcinoma were absent. Adenocarcinoma had the lowest specificity (84.4%, 95% CI = 79.0% to 88.9%), negative predictive value (85.2%, 95% CI = 79.9% to 89.6%), and percent exact agreement (82.9%, 95% CI = 79.2% to 86.6%). Samples collected by cytologic examination (odds ratio [OR] = 2.4, 95% CI = 1.1 to 5.2) or biopsy examination (OR = 2.2, 95% CI = 1.1 to 4.2) were more likely to be misclassified than samples obtained via resection. Thus, the histologic type obtained by the Iowa Cancer Registry is reasonably reliable, but independent slide review is needed for precise histologic typing of lung cancer.